Description
Tulobuterol is a long-acting β2-adrenergic receptor agonist that is clinically used in some countries to treat chronic obstructive pulmonary disorder (COPD) and asthma. Tulobuterol exhibits bronchodilatory, anti-inflammatory, and antiviral activities. Tulobuterol treats pulmonary disorders by inducing relaxation of airway smooth muscle cells. In tracheal epithelial cells, tulobuterol also prevents activation of NF-κB and decreases levels of ICAM-1, IL-1β, IL-6, and IL-8, inhibiting rhinovirus replication.
References
Yamaya M, Nishimura H, Nadine L, et al. Tulobuterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Physiol Rep. 2013 Aug;1(3):e00041. PMID: 24303127.
Katsunuma T, Fujisawa T, Nagao M, et al. Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years. Allergol Int. 2013 Mar;62(1):37-43. PMID: 23000726.
Terpstra GK, Raaijmakers JA. Beta-agonistic properties of tulobuterol, a new beta-sympathicomimetic drug, and its effects on pulmonary beta-adrenoceptor characteristics. Lung. 1990;168 Suppl:179-85. PMID: 1974673.
Ruff F, Zander JF, Edoute Y, et al. Beta-2 adrenergic responses to tulobuterol in airway smooth muscle, vascular smooth muscle and adrenergic nerves. J Pharmacol Exp Ther. 1988 Jan;244(1):173-80. PMID: 2826765.
